{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:07Z","timestamp":1789510627627,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.radonc.2020.07.057","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T02:54:02Z","timestamp":1596682442000},"page":"275-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-118X","authenticated-orcid":false,"given":"Charlotte S.","family":"Voskuilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike W.","family":"van de Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannet","family":"Schuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"Pos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva E.","family":"Schaake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.07.057_b0005","author":"Witjes","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.07.057_b0010","doi-asserted-by":"crossref","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline. J Urol 2017;198:552\u20139. doi:10.1016\/j.juro.2017.04.086.","DOI":"10.1016\/j.juro.2017.04.086"},{"key":"10.1016\/j.radonc.2020.07.057_b0015","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines - Bladder Cancer (Version 1.2019) 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (accessed August 2, 2019)."},{"key":"10.1016\/j.radonc.2020.07.057_b0020","doi-asserted-by":"crossref","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477\u201388. doi:10.1056\/NEJMoa1106106.","DOI":"10.1056\/NEJMoa1106106"},{"key":"10.1016\/j.radonc.2020.07.057_b0025","doi-asserted-by":"crossref","unstructured":"Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, Shariat SF, Shipley WU, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review 2014;66:120\u201337. doi:10.1016\/j.eururo.2014.02.038.","DOI":"10.1016\/j.eururo.2014.02.038"},{"key":"10.1016\/j.radonc.2020.07.057_b0030","doi-asserted-by":"crossref","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579\u201388. doi:10.1016\/S1470-2045(12)70116-X.","DOI":"10.1016\/S1470-2045(12)70116-X"},{"key":"10.1016\/j.radonc.2020.07.057_b0035","doi-asserted-by":"crossref","unstructured":"Peixoto RDA, Wan DD, Schellenberg D, Lim HJ. A comparison between 5-fluorouracil\/mitomycin and capecitabine\/mitomycin in combination with radiation for anal cancer. J Gastrointest Oncol 2016;7:665\u201372. doi:10.21037\/jgo.2016.06.04.","DOI":"10.21037\/jgo.2016.06.04"},{"key":"10.1016\/j.radonc.2020.07.057_b0040","doi-asserted-by":"crossref","unstructured":"Jones CM, Adams R, Downing A, Glynne-Jones R, Harrison M, Hawkins M, et al. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. Int J Radiat Oncol Biol Phys 2018;101:1202\u201311. doi:10.1016\/j.ijrobp.2018.04.033.","DOI":"10.1016\/j.ijrobp.2018.04.033"},{"key":"10.1016\/j.radonc.2020.07.057_b0045","doi-asserted-by":"crossref","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD2A to individualize fluoropyrimidine therapy: A safety and cost analysis. J Clin Oncol 2016;34:227\u201334.","DOI":"10.1200\/JCO.2015.63.1325"},{"key":"10.1016\/j.radonc.2020.07.057_b0050","doi-asserted-by":"crossref","unstructured":"Pos F, Bex A, Dees-Ribbers HM, Betgen A, van Herk M, Remeijer P. Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancer. Radiother Oncol 2009;93:364\u20137. doi:10.1016\/j.radonc.2009.09.003.","DOI":"10.1016\/j.radonc.2009.09.003"},{"key":"10.1016\/j.radonc.2020.07.057_b0055","unstructured":"National Cancer Institute (NCI)\/National Institute of Health (NIH). Common Terminology Criteria for Adverse Events v.5.0 (CTCAE). 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."},{"key":"10.1016\/j.radonc.2020.07.057_b0060","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg 2004;240:205\u201313. doi:10.1097\/01.sla.0000133083.54934.ae.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"10.1016\/j.radonc.2020.07.057_b0065","first-page":"2","article-title":"Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: Systematic review and meta-analysis","volume":"10","author":"Souza","year":"2016","journal-title":"E Cancer Med Sci"},{"key":"10.1016\/j.radonc.2020.07.057_b0070","doi-asserted-by":"crossref","unstructured":"Patel B, Forman J, Fontana J, Frazier A, Pontes E, Vaishampayan U. A single institution experience with concurrent capecitabine and radiation therapy in weak and\/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys 2005;62:1332\u20138. doi:10.1016\/j.ijrobp.2005.01.004.","DOI":"10.1016\/j.ijrobp.2005.01.004"},{"key":"10.1016\/j.radonc.2020.07.057_b0075","doi-asserted-by":"crossref","unstructured":"Leng J, Akthar AS, Szmulewitz RZ, O\u2019Donnell PH, Sweis RF, Pitroda SP, et al. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer 2019;17:e12\u20138. doi:10.1016\/j.clgc.2018.10.003.","DOI":"10.1016\/j.clgc.2018.10.003"},{"key":"10.1016\/j.radonc.2020.07.057_b0080","doi-asserted-by":"crossref","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer \u2014 NEJM 2003:859\u201366.","DOI":"10.1056\/NEJMoa022148"},{"key":"10.1016\/j.radonc.2020.07.057_b0085","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.07.057_b0090","doi-asserted-by":"crossref","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952\u201360. doi:10.1016\/j.eururo.2016.12.020.","DOI":"10.1016\/j.eururo.2016.12.020"},{"key":"10.1016\/j.radonc.2020.07.057_b0095","doi-asserted-by":"crossref","unstructured":"Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol 2014;66:1065\u201377. doi:10.1016\/j.eururo.2014.05.031.","DOI":"10.1016\/j.eururo.2014.05.031"},{"key":"10.1016\/j.radonc.2020.07.057_b0100","doi-asserted-by":"crossref","unstructured":"Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, et al. Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer. J Urol 2018. doi:10.1016\/j.juro.2018.10.007.","DOI":"10.1016\/j.juro.2018.10.007"},{"key":"10.1016\/j.radonc.2020.07.057_b0105","doi-asserted-by":"crossref","unstructured":"Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol 2018;19:e683\u201395. doi:10.1016\/S1470-2045(18)30693-4.","DOI":"10.1016\/S1470-2045(18)30693-4"},{"key":"10.1016\/j.radonc.2020.07.057_b0110","doi-asserted-by":"crossref","unstructured":"Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur Urol 2019:1\u201310. doi:10.1016\/j.eururo.2019.01.011.","DOI":"10.1016\/j.eururo.2019.01.011"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020307167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020307167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:11:12Z","timestamp":1779811872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020307167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"alternative-id":["S0167814020307167"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.07.057","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.07.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}